Compare LAB & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | SLP |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | 389 | 213 |
| Industry | Biotechnology: Laboratory Analytical Instruments | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.2M | 370.7M |
| IPO Year | 2008 | 1996 |
| Metric | LAB | SLP |
|---|---|---|
| Price | $0.83 | $18.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.35 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 4.5M | 577.8K |
| Earning Date | 05-05-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | N/A |
| EPS | 0.33 | ★ 0.43 |
| Revenue | ★ $101,937,000.00 | $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | $2.63 | $5.90 |
| P/E Ratio | ★ $2.65 | $42.63 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $0.70 | $11.09 |
| 52 Week High | $1.72 | $21.01 |
| Indicator | LAB | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 65.07 |
| Support Level | $0.79 | $17.74 |
| Resistance Level | $1.01 | $18.57 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 30.41 | 64.58 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.